Background There is a wide range in the reported prevalences of depression in patients with systemic lupus erythematosus (SLE), while the prevalence of depression in patients with cutaneous lupus erythematosus (CLE) remains severely understudied. Objectives To examine whether patients with SLE or CLE have an increased risk of depression. Methods In this nationwide observational cohort study, we included patients aged ≥ 18 years with a first-time diagnosis of SLE or CLE between 2000 and 2015 identified in the Danish National Patient Register, which were matched with the general population in a ratio of 1 : 10. After linkage to national Danish health registers of primary and secondary care, analyses of risk for depression and antidepressant use were performed using Cox regression models adjusted for age, sex, socioeconomic status, smoking, alcohol abuse, prior depression and prior antidepressant use. Results A total of 3489 patients with lupus erythematosus were followed for 23 373 person-years. Compared with the general population, the adjusted hazard ratios (HRs) of depression were 2Á07 [95% confidence interval (CI) 1Á55-2Á75] and 2Á22 (95% CI 1Á77-2Á77) for patients with CLE and SLE, respectively; for hospitalization owing to depression at a department of psychiatry HRs were 2Á63 (95% CI 0Á80-8Á67) and 3Á52 (95% CI 1Á53-8Á11) for patients with CLE and SLE, respectively. The adjusted HRs for antidepressant use were 1Á47 (95% CI 1Á34-1Á63) and 1Á70 (95% CI 1Á58-1Á83) for patients with CLE and SLE, respectively. Conclusions The risk of depression was significantly increased in patients with SLE and CLE. Awareness of an increased risk of depression in patients with SLE and CLE might be warranted.
Summary
Background There is a wide range in the reported prevalences of depression in patients with systemic lupus erythematosus (SLE), while the prevalence of depression in patients with cutaneous lupus erythematosus (CLE) remains severely understudied. Objectives To examine whether patients with SLE or CLE have an increased risk of depression. Methods In this nationwide observational cohort study, we included patients aged ≥ 18 years with a first-time diagnosis of SLE or CLE between 2000 and 2015 identified in the Danish National Patient Register, which were matched with the general population in a ratio of 1 : 10. After linkage to national Danish health registers of primary and secondary care, analyses of risk for depression and antidepressant use were performed using Cox regression models adjusted for age, sex, socioeconomic status, smoking, alcohol abuse, prior depression and prior antidepressant use. Results A total of 3489 patients with lupus erythematosus were followed for 23 373 person-years. Compared with the general population, the adjusted hazard ratios (HRs) of depression were 2Á07 [95% confidence interval (CI) 1Á55-2Á75] and 2Á22 (95% CI 1Á77-2Á77) for patients with CLE and SLE, respectively; for hospitalization owing to depression at a department of psychiatry HRs were 2Á63 (95% CI 0Á80-8Á67) and 3Á52 (95% CI 1Á53-8Á11) for patients with CLE and SLE, respectively. The adjusted HRs for antidepressant use were 1Á47 (95% CI 1Á34-1Á63) and 1Á70 (95% CI 1Á58-1Á83) for patients with CLE and SLE, respectively. Conclusions The risk of depression was significantly increased in patients with SLE and CLE. Awareness of an increased risk of depression in patients with SLE and CLE might be warranted.
What's already known about this topic?
• There is a wide range in the reported prevalences of depression in patients with systemic lupus erythematosus, while the prevalence of depression in patients with cutaneous lupus erythematosus remains severely understudied.
What does this study add?
• In this nationwide cohort study, patients with cutaneous or systemic lupus erythematosus had a twofold increased risk of depression compared with the general population in Denmark.
• The risk of self-harm and death from suicide were not significantly increased in patients with lupus erythematosus.
Lupus erythematosus (LE) is a chronic autoimmune disease, which may present in a systemic or a localized cutaneous form. As the name suggests, systemic LE (SLE) may not only involve the skin but also internal organs such as the lungs, heart and kidneys, whereas cutaneous LE (CLE) is mainly restricted to the skin. 1 Quality of life is considerably impaired for patients with SLE and also for patients with CLE. 2, 3 In patients with SLE, the prevalence of depression ranges from 2 to 92% depending on factors such as study design and diagnostic criteria, 4 while the prevalence of depression in patients with CLE remains severely understudied. Likewise, data on the incidence of depression in adults with a diagnosis of CLE or SLE remain scarce.
As depression is associated with morbidity, decreased quality of life, and increased mortality for the individual patient, 5, 6 in addition to a high economic burden on society, 7 it is important to investigate whether patients with CLE or SLE have an increased risk of depression. We therefore investigated the association between LE and risk of depression in a nationwide cohort of the Danish population.
Materials and methods

Study design
A nationwide longitudinal cohort study was performed to examine whether patients with SLE or CLE have an increased risk of depression.
Data sources
Nationwide Danish health registers were used to conduct the study. In Denmark, each resident is given a unique lifelong Civil Personal Register (CPR) number at birth or upon immigration to Denmark. This CPR number makes it possible to cross-link a wide range of national health registers. From the Danish Civil Registration System, information on date of birth, sex, migration, ethnicity and vital status were obtained. 8 Diagnoses were acquired from the Danish National Patient Register (DNPR). The Danish National Health Service Register (NHSR) contains information from health contractors in primary care and is part of the tax-funded public healthcare system. 9 Data were also obtained from the Register of Medicinal Products Statistics that contains information on all pharmacy-dispensed and redeemed prescriptions since 1995. 10 The data regarding suicides were obtained from the Register of Causes of Death. 11 Finally, information on socioeconomic status was calculated based on data from the Income Statistics
Register. 12 An elaboration on the description of the data sources is provided in File S1 (see Supporting Information).
Study population
The source population comprised all residents in Denmark aged ≥ 18 years from 2000 to 2015. People aged < 18 years were added to the study on the day after their 18th birthday. We identified all patients with a first-time diagnosis of CLE or SLE, either as a primary or supplementary diagnosis (Table S1 ; see Supporting Information). Patients with a diagnosis of CLE or SLE before baseline were excluded. The baseline or index date for CLE or SLE was the date of the first diagnosis, and each case was matched for age, sex and index date in a ratio of 1 : 10 with individuals from the general population serving as a reference group. The fact that the reference group was matched to the index data meant that patients in the reference population had to be alive, resident in the source population and at risk of developing SLE or CLE at the date of the SLE/CLE diagnosis for the corresponding case. The index date for the matched population was the index date for the corresponding cases. The study population was followed from 1 January 2000 to 31 December 2015 or date of emigration, death or the occurrence of an end point, whichever occurred first. The patients were matched with a reference population for age and sex.
Covariates
A proxy for smoking was assessed using data on drugs prescribed for smoking cessation, diagnoses of smoking, tobacco use, chronic obstructive pulmonary disease, lung cancer, or treatments and/or therapeutic interventions aimed at smoking cessation. 13 Alcohol abuse was assessed using diagnoses of alcohol abuse or conditions strongly related to alcohol abuse, pharmacological treatment with drugs used for alcohol dependence, and treatment interventions for alcohol dependence.
14 Socioeconomic status was defined by the average household income for the 5 years preceding index and was divided into age-standardized quintiles.
Baseline depression was defined as a diagnosis of depression up to 5 years prior to index.
Outcomes
The primary study end point was depression, defined by either a diagnosis of depression recorded in the DNPR [International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) codes F32 or F33] or depression registered by psychologists or general practitioners (GPs) in the NHSR (Table S1 ; see Supporting Information). For depression recorded by GPs, the registration was the use of the Hamilton Rating Scale for Depression, which is a test used to assess the severity of depression. For psychologists, the registration was a consultation owing to depression.
The secondary end point was a redeemed prescription for antidepressants.
Statistical analysis
Continuous variables were presented as mean with SD if normally distributed or as median with interquartile range if the distribution was skewed, and frequencies with percentages were used for categorical data.
Incidence rates (IRs) of depression and antidepressant use were determined for patients with CLE, SLE and the general population and expressed as the number of events per 1000 person-years (PYs). Analyses of depression risk were performed in Cox regression models using calendar time as the time scale and were adjusted for sex, age, smoking, alcohol abuse, socioeconomic status, previous depression and prior antidepressant use. The variable 'ethnicity' was not found to be significant in the univariate analysis and thus was not included in the adjusted Cox regression model. Smoking, alcohol abuse, sex, previous depression and prior antidepressant use were all treated as binary variables in the analysis, whereas age was treated as a continuous variable, and socioeconomic status was treated as a categorical variable. Smoking, alcohol abuse and LE status were included as time-dependent variables. Treating LE status as a time-dependent variable made it possible to change status from CLE to SLE but not from SLE to CLE. Model assumptions, including the proportional hazards assumption, were tested and found to be valid.
For reasons of clinical relevance, we performed subgroup analyses by sex, age (< 50 years or ≥ 50 years at LE diagnosis) and severe depression, which was defined as patients hospitalized for depression at a hospital in general or at a department of psychiatry.
We considered a two-sided P-value < 0Á05 to be statistically significant. Data management and statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, U.S.A.) and Stata/MP version 14 (StataCorp, College Station, TX, U.S.A.).
Sensitivity analyses
Firstly, we limited our study to patients with a CLE or SLE diagnosis made by a rheumatologist, dermatologist or nephrologist in order to be more certain of an accurate diagnosis. Secondly, to increase the validity of the definition of SLE we identified patients with SLE in two different ways; in one sensitivity analysis we used a previously validated algorithm for SLE with a positive predictive value of 89%, 15 and in another we included only patients with SLE who had received systemic therapies such as methotrexate, hydroxychloroquine and systemic corticosteroids during follow-up. Furthermore, we performed a sensitivity analysis excluding patients diagnosed with depression within 3 months of their first LE diagnosis in order to determine whether depression was a neuropsychiatric manifestation at the time of LE diagnosis or whether depression was more prominent as a long-term outcome of LE. We also carried out an analysis in which we excluded patients with prior depression (defined as 5 years before index) and prior antidepressant use (defined as 12 months before index). Additionally, we conducted a sensitivity analysis in which we used LE status as a fixed variable. Patients with a diagnosis of both CLE and SLE comprised a separate group. To address surveillance bias, we performed a sensitivity analysis with an outcome that we did not believe to be associated with LE. Our outcome was azithromycin, used only for the treatment of chlamydia (defined as 1 g of azithromycin in a single dose).
Results
The study comprised 1424 and 2065 patients with CLE and SLE, respectively, matched with 34 890 people from the general population in Denmark.
Baseline characteristics of our study population are shown in Table 1 . Overall, the median age for the first diagnosis of CLE or SLE at a hospital was approximately 51 years; however, patients with CLE were slightly older. More patients with LE smoked and abused alcohol compared with the general population.
Overall, we found that 51 patients with CLE, 89 patients with SLE and 653 people in the general population were diagnosed with depression. For depression, the follow-up times were 8103, 15 270 and 253 547 PYs for CLE, SLE and the general population, respectively; the corresponding IRs were 6Á29 (95% CI 4Á78-8Á28), 5Á83 (95% CI 4Á74-7Á17) and 2Á58 (95% CI 2Á24-2Á78) per 1000 PYs.
The numbers of patients using antidepressants were 419 in the CLE group, 790 in the SLE group and 8224 in the general population. For antidepressant use, the follow-up times were 6222, 11 074, and 212 148 PYs for CLE, SLE and the general population, respectively; the corresponding IRs were 67Á34 (95% CI 61Á19-74Á10), 71Á34 (95% CI 66Á53-76Á49) and 38Á77 (95% CI 37Á94-39Á61) per 1000 PYs.
The period prevalence of depression corresponding to the study period was 3Á6% in patients with CLE, 4Á3% in patients with SLE and 1Á9% in the general population. The same pattern was observed for antidepressant use with period prevalences of 29Á4%, 38Á3% and 23Á6% in patients with CLE, patients with SLE and the general population, respectively.
The use of hydroxychloroquine, methotrexate, systemic corticosteroids and topical corticosteroids increased during follow-up compared with baseline use (data not shown). However, only 50Á1% of patients with CLE and 46Á5% of patients with SLE were treated with hydroxychloroquine during follow-up.
Diagnoses of LE were associated with a significantly increased risk of depression. When adjusting for age, sex, smoking, alcohol abuse, socioeconomic status, prior depression and prior antidepressant use the HRs were 2Á07 (95% CI 1Á55-2Á75) and 2Á22 (95% CI 1Á77-2Á77) for patients with CLE and SLE, respectively (Table 2) .
In a subgroup analysis, we found that patients with LE had an increased risk of severe depression compared with the general population. For patients who were hospitalized for depression at a general hospital, the adjusted HRs were 2Á90 (95% CI 1Á32-6Á36) and 2Á60 (95% CI 1Á32-5Á06) for patients with CLE and SLE, respectively. However, for patients hospitalized for depression at a department of psychiatry, the adjusted HRs were 2Á63 (95% CI 0Á80-8Á67) and 3Á52 (95% CI 1Á53-8Á11) for patients with CLE and SLE, respectively (Table S2; see Supporting Information) .
Likewise, a significant association was found between LE and antidepressant use. The adjusted HRs were 1Á47 (95% CI 1Á34-1Á63) and 1Á70 (95% CI 1Á58-1Á83) for patients with CLE and SLE, respectively ( Table 2 ). The HR for each covariate is presented in Table S3 (see Supporting Information).
The risk of depression was more pronounced in patients diagnosed with CLE or SLE who were aged < 50 years, especially for patients with CLE. The adjusted HRs were 3Á15 (95% CI 2Á02-4Á92) and 2Á28 (95% CI 1Á60-3Á25) for patients with CLE and SLE who were aged < 50 years. For antidepressant use, the stratification in age did not alter the results significantly (Table 2) .
When stratifying according to sex, the risk of depression or antidepressant use was significantly increased for both men and women. Men with CLE had a higher risk of depression than women. For antidepressant use, men with SLE had the highest risk (Table S4 ; see Supporting Information).
In a post hoc analysis, we found that, in general, death from suicide was seldom; there were only three completed suicides in the LE group and 43 completed suicides in the general population. The crude HR was 0Á72 (95% CI 0Á22-2Á31, P = 0Á576) and the adjusted HR was 0Á55 (95% CI 0Á17-1Á78, P = 0Á316) for completed suicides in the group of patients with LE compared with the general population. Likewise, cases of self-harm were seldom, with three cases in the LE group and 31 cases in the general population. The crude HR for cases of self-harm in the LE group compared with the general population was 1Á00 (95% CI 0Á30-3Á26, P = 0Á995) and the adjusted HR was 0Á78 (95% CI 0Á24-2Á58, P = 0Á689). Baseline medication is a redeemed prescription up to 12 months prior to index. Data are provided as n (%) unless otherwise stated.
Sensitivity analyses
We excluded patients with prior depression or prior antidepressant use from the analyses, which did not alter the clear trends in the study results (Table S5 ; see Supporting Information). Moreover, the results were not altered significantly when we excluded patients diagnosed with depression within 3 months of their first LE diagnosis (data not shown). When using a previously validated algorithm 15 for defining patients with SLE, we found that the adjusted HRs were 2Á04 (95% CI 1Á31-3Á19) for depression and 1Á56 (95% CI 1Á36-1Á79) for antidepressant use (Table S6 ; see Supporting Information). When we included only patients with SLE on systemic therapies, such as methotrexate, hydroxychloroquine and systemic corticosteroids during follow-up, we found that the statistical significance was retained; the adjusted HRs were 2Á48 (95% CI 1Á87-3Á30, P < 0Á001) for depression and 1Á78 (95% CI 1Á63-1Á94, P < 0Á001) for antidepressant use. In the sensitivity analysis in which we included only patients with CLE or SLE diagnosed from a department of rheumatology, dermatology or nephrology, the results were not notably altered (Table S7 ; see Supporting Information). In the sensitivity analysis with CLE and SLE status as fixed variables the results were not significantly altered (Table S8 ; see Supporting Information). Finally, in the sensitivity analysis where the outcome was treatment with azithromycin for chlamydia, we found a crude HR of 1Á31 (95% CI 1Á04-1Á65) and an adjusted HR of 1Á17 (95% CI 0Á93-1Á48) for patients with LE compared with the general population.
Discussion
In this nationwide cohort study examining the risk of depression in patients with LE, we found a twofold increased risk of depression in patients with CLE or SLE compared with a matched group from the general population in Denmark. The risk for depression was of similar magnitude in the two groups, which indicates that the involvement of the skin has a similarly important impact as the systemic disease. The reason for the increased risk of depression in patients with SLE remains unclear. This is probably due to both direct and indirect consequences of the disease; a direct consequence of the systemic inflammation and an indirect consequence of the psychological burden of having and coping with a chronic disease. [16] [17] [18] [19] [20] Previous studies have shown that depression is associated with inflammation. Levels of proinflammatory cytokines such as interleukin (IL)-6, IL-1b and tumour necrosis factor (TNF)-a are increased in patients with depression. 16, 17 A study has shown that sera TNF-a levels are increased in patients with SLE and concomitant depressive symptoms. 19 However, a systematic review found that psychological factors were the most frequently reported cause for the association between SLE and depression. 18 The association between an autoimmune disease and a neuropsychiatric disease is also found in other autoimmune diseases besides LE, for example in patients with rheumatoid arthritis. 21, 22 In general, patients with dermatological diseases have a reduced quality of life and have an increased prevalence of psychiatric morbidity including depression.
2 This is shown in previous studies where an association between depression and atopic dermatitis, 23 rosacea 24 and psoriasis 25 is found, which is in line with our findings regarding CLE and the increased risk of depression and antidepressant use.
A systematic review and meta-analysis from 2017 with 59 studies reporting on a total of 10 828 patients with SLE found that the prevalence of depression ranged from 2 to 92% among the studies. 4 This diversity is due to variations in the study design, sample size, country and different definitions of Table 2 Crude and adjusted hazard ratios (HRs) for depression and antidepressant use in patients with lupus erythematosus compared with the general population and stratified for age (< 50 years and ≥ 50 years at diagnosis of lupus erythematosus)
Crude HR 95% CI P-values Adjusted HR a 95% CI P-values
Age < 50 years Age ≥ 50 years Adjusted HR a 95% CI P-value Adjusted HR a 95% CI P-value
CI, confidence interval; CLE, cutaneous lupus erythematosus; SLE, systemic lupus erythematosus. depression. The meta-analysis showed that the pooled prevalence of depression in patients with SLE was 24% (95% CI 16-31%) when using the Diagnostic and Statistical Manual of Mental Disorders and/or ICD diagnostic criteria. 4 This prevalence is higher than the period prevalence of depression (4Á3%) and slightly lower than the period prevalence for antidepressant use (31Á9%) found in our study. This indicates that the 'true' prevalence of depression is somewhere between these prevalences. The reason for the discrepancy could be that we encounter too few patients with depression (see limitations below) and these tend to be only the severe cases (patients seen at a hospital, seen by a psychologist or having a Hamilton Rating Scale for Depression test carried out by a GP). In contrast to SLE, there is a lack of information regarding the association of patients with CLE and depression. Only one previous study with a small sample size has examined the prevalence and odds ratio (OR) of depression in patients with CLE. 26 This study showed a point prevalence of 9% for depression, a lifetime prevalence of 44% and an OR of 2Á5 (95% CI 1Á2-5Á0) for lifetime depression in patients with CLE. 26 The suicide risk is increased in patients with depression. 6 In our study, the number of attempts and completed suicides was low and was not increased in patients with LE compared with the general population. Previous studies have described that suicidal ideation is common in patients with SLE and that the IRs of completed suicides and attempts are also increased. 27, 28 Several limitations of our study need to be addressed. One limitation of the study is that some patients with CLE were followed up by their private dermatologist or GP. Therefore, our results cannot be generalized to these patients who probably have a less severe disease burden and a lower risk of depression than patients who were followed up in hospitals. Conversely, patients with SLE are typically followed up at a hospital. 29 Another limitation is the risk of not including all patients with depression. Firstly, far from all patients with depression are seen at a hospital. Secondly, there is a possibility that not all GPs use the Hamilton Rating Scale for Depression to assess the depression severity, even though they are charged for it. This will mean that the risk of depression is underestimated in all groups. On the other hand, patients with LE receive increased medical scrutiny compared with the general population, potentially giving rise to surveillance bias, i.e. increased contact with healthcare professionals thereby increasing the likelihood of being diagnosed with depression. However, thirdly, fatigue and other symptoms of mood disorders are common in patients with SLE, thus patients' complaints might be classified as symptoms of SLE and not depression. In the current study, we did not include the ICD-10 depression test or psychometric test for depression, as this would overestimate the risk of depression in each group because not everyone who takes the test will be diagnosed with depression. The use of antidepressants as a surrogate marker for depression is not completely accurate as some patients treated with antidepressants are treated for anxiety, sleeping disorder or obsessive-compulsive disorder. 30 A study showed that the main indication in Denmark for treatment with antidepressants was depression followed by anxiety. 31 The strengths of our study include the nationwide covered registers with virtually complete follow-up, which was conducted in a country with free healthcare. Likewise, the long follow-up period and the large number of patients represent major strengths of our study. To our knowledge, we are the first to examine the risk of depression in patients with SLE compared with a general population. We attempted to adjust for important confounders such as smoking and alcohol abuse by using proxies. However, the use of these proxies may result in residual confounding. Furthermore, we performed numerous sensitivity analyses, including a validated algorithm to identify patients with SLE, and none of these altered the results significantly. Likewise, we carried out a sensitivity analysis with azithromycin as the outcome where the magnitude of the HR suggests slight surveillance bias; however, this is unlikely to explain our results fully. Owing to the observational study design, we cannot reach any conclusions regarding causality, even though the sensitivity analysis excluding patients diagnosed with depression within 3 months of their first LE diagnosis gives the impression that depression is a long-term outcome of LE, or at least makes it less convincing that depression is due to a neuropsychiatric manifestation at the time of LE diagnosis.
We found a significantly increased risk of depression in patients with CLE and SLE compared with a matched group from the general population in Denmark. The risk for depression is of similar magnitude in both groups, indicating that the involvement of the skin in addition to systemic involvement affects the overall risk of depression. Notably, rheumatologists and dermatologists should be aware of the increased risk of depression in patients with LE.
Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher's website:
File S1 Supplementary materials and methods. Table S1 Codes used in the article. Table S2 Crude and adjusted hazard ratios for severe depression diagnosed at hospital in general or at department of psychiatry in patients with lupus erythematosus compared with the general population. Table S3 Adjusted hazard ratios for depression in patients with lupus erythematosus compared with the general population.
Table S4 Adjusted hazard ratios in patients with lupus erythematosus compared with the general population stratified for sex. Table S5 Adjusted hazard ratios for depression and antidepressant use in patients with lupus erythematosus compared with the general population where patients with prior depression (defined as 5 years before index) or antidepressant use (12 months before index) are excluded. Table S6 Using a validated algorithm to find patients with systemic lupus erythematosus (SLE) and to determine the crude and adjusted hazard ratios for depression and antidepressant use in patients with SLE compared with the general population. Table S7 Crude and adjusted hazard ratios for depression and antidepressant use in patients with lupus erythematosus (LE) compared with the general population where only patients with LE diagnosed at a department of rheumatology, dermatology or nephrology are included. Table S8 Crude and adjusted hazard ratios for depression and antidepressant use in patients with lupus erythematosus [grouped according to patients with systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and a group of both SLE and CLE] using lupus erythematosus status as a fixed variable.
Powerpoint S1 Journal Club Slide Set.
